Helius Medical Technologies (HMTI) filed an updated Prospectus Supplement for the offer and sale of up to $25 million of shares through the Agent pursuant to the Sales Agreement.
On June 23, 2023, Helius Medical Technologies, Inc. entered into a Sales Agreement with Roth Capital Partners, LLC, as sales agent. Pursuant to this agreement, the company may offer and sell shares of its common stock.
Helius Medical Technologies plans to utilize the net proceeds from the offering for working capital and general corporate purposes. These purposes may include funding commercialization efforts and research and development activities.
The shares have been registered under the Securities Act of 1933, as amended, pursuant to the Registration Statement on Form S-3 and the Prospectus of Helius Medical Technologies.
